NO20052860L - Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme - Google Patents
Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av sammeInfo
- Publication number
- NO20052860L NO20052860L NO20052860A NO20052860A NO20052860L NO 20052860 L NO20052860 L NO 20052860L NO 20052860 A NO20052860 A NO 20052860A NO 20052860 A NO20052860 A NO 20052860A NO 20052860 L NO20052860 L NO 20052860L
- Authority
- NO
- Norway
- Prior art keywords
- pellet
- acrylic polymer
- water
- cores
- tamsulosin
- Prior art date
Links
- 239000008188 pellet Substances 0.000 title abstract 13
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 title abstract 2
- 229960002613 tamsulosin Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229920000058 polyacrylate Polymers 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 239000008199 coating composition Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- 229960003198 tamsulosin hydrochloride Drugs 0.000 abstract 2
- 239000011247 coating layer Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000010410 layer Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/293,940 US7018658B2 (en) | 2002-11-14 | 2002-11-14 | Pharmaceutical pellets comprising tamsulosin |
| PCT/NL2002/000821 WO2004043449A1 (en) | 2002-11-14 | 2002-12-12 | Pharmaceutical pellets comprising tamsulosin and a process for making the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052860D0 NO20052860D0 (no) | 2005-06-13 |
| NO20052860L true NO20052860L (no) | 2005-08-10 |
Family
ID=23131212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052860A NO20052860L (no) | 2002-11-14 | 2005-06-13 | Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7018658B2 (de) |
| EP (1) | EP1562573B1 (de) |
| JP (1) | JP5405710B2 (de) |
| AT (2) | ATE323478T1 (de) |
| AU (3) | AU2002351451A1 (de) |
| BE (1) | BE1015435A4 (de) |
| CA (1) | CA2415840C (de) |
| CH (1) | CH696419A5 (de) |
| CZ (1) | CZ13341U1 (de) |
| DE (2) | DE20219293U1 (de) |
| DK (2) | DK1562573T3 (de) |
| ES (1) | ES2257589T3 (de) |
| FI (1) | FI5842U1 (de) |
| FR (1) | FR2847166B1 (de) |
| GB (1) | GB2395125B (de) |
| HU (1) | HUP0500832A3 (de) |
| NL (1) | NL1022151C2 (de) |
| NO (1) | NO20052860L (de) |
| PL (1) | PL206083B1 (de) |
| PT (1) | PT1562573E (de) |
| SI (1) | SI21394A2 (de) |
| WO (2) | WO2004043449A1 (de) |
| ZA (1) | ZA200503696B (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8323692B2 (en) | 2002-02-21 | 2012-12-04 | Valeant International Bermuda | Controlled release dosage forms |
| CA2476496C (en) * | 2002-02-21 | 2009-12-15 | Biovail Laboratories Inc. | Controlled release dosage forms |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US7018658B2 (en) * | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
| EP1638537A1 (de) * | 2003-07-01 | 2006-03-29 | KRKA, tovarna zdravil, d.d., Novo mesto | Tamsulosin-kern mit einem überzug aus polyvinylpyrrolidon und polyvinylacetat |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US20050106253A1 (en) * | 2003-11-13 | 2005-05-19 | Platteeuw Johannes J. | Pharmaceutical pellets comprising tamsulosin |
| WO2005053659A1 (en) * | 2003-12-03 | 2005-06-16 | Natco Pharma Limited | An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation |
| SI21637A (sl) * | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Farmacevtska oblika z nadzorovanim sproščanjem |
| KR100615952B1 (ko) * | 2004-05-27 | 2006-08-28 | 한국화학연구원 | 서방형 약물 전달 시스템 |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| SI1618873T1 (sl) * | 2004-07-14 | 2007-10-31 | Siegfried Generics Int Ag | Granulat za kontrolirano sproščanje tamsulozina, ki vsebuje alginat |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| WO2007017253A1 (de) * | 2005-08-10 | 2007-02-15 | Add Advanced Drug Delivery Technologies Ltd. | Orales präparat mit kontrollierter freisetzung eines benzolsulfonamids |
| KR20070021806A (ko) * | 2005-08-19 | 2007-02-23 | (주)아모레퍼시픽 | α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법 |
| KR100745515B1 (ko) * | 2006-04-10 | 2007-08-02 | 주식회사 대웅제약 | 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법 |
| WO2007131804A1 (en) * | 2006-05-17 | 2007-11-22 | Synthon B.V. | Tablet composition with a prolonged release of tamsulosin |
| US20090004284A1 (en) * | 2007-06-26 | 2009-01-01 | Watson Pharmaceuticals, Inc. | Controlled release tamsulosin hydrochloride formulation |
| EP2047847A1 (de) * | 2007-10-12 | 2009-04-15 | KRKA, tovarna zdravil, d.d., Novo mesto | Feste pharmazeutische Zusammensetzung mit Tamsulosin |
| EP2217228B1 (de) * | 2007-10-12 | 2012-04-04 | Krka Tovarna Zdravil, D.D., Novo Mesto | Feste pharmazeutische zusammensetzung mit tamsulosin |
| US20110244033A1 (en) * | 2008-12-09 | 2011-10-06 | Denny Johan Marijn Van Den Heuvel | Tamsulosin pellets for fixed dose combination |
| US8465770B2 (en) * | 2008-12-24 | 2013-06-18 | Synthon Bv | Low dose controlled release tablet |
| EP2456424B1 (de) | 2009-07-22 | 2013-08-28 | Grünenthal GmbH | Manipulationssichere oxidations-stabilisierte darreichungsform |
| CN103269688A (zh) | 2010-09-02 | 2013-08-28 | 格吕伦塔尔有限公司 | 包含无机盐的抗破碎剂型 |
| WO2012110092A1 (en) | 2011-02-17 | 2012-08-23 | Synthon Bv | Tamsulosin derivatives |
| KR20140053159A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
| EA201400173A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
| WO2013123965A1 (en) | 2012-02-20 | 2013-08-29 | Synthon Bv | A fixed dose pharmaceutical formulation |
| EP2838512B1 (de) | 2012-04-18 | 2018-08-22 | Grünenthal GmbH | Fälschungssichere und dose dumping sichere pharmazeutische darreichungsform |
| BR112015024348A2 (pt) | 2013-06-21 | 2017-07-18 | Wockhardt Ltd | composições farmacêuticas de tansulosina ou sais destas |
| EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
| CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| EP2949319A1 (de) | 2014-05-26 | 2015-12-02 | Galenicum Health S.L. | Pharmazeutische zusammensetzungen mit einem wirkstoff |
| CZ2015225A3 (cs) * | 2015-03-30 | 2016-10-12 | Zentiva, K.S. | Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| CN105287395A (zh) * | 2015-11-19 | 2016-02-03 | 哈尔滨圣吉药业股份有限公司 | 一种盐酸坦索罗辛缓释微丸及其制备方法 |
| KR102391495B1 (ko) | 2016-03-31 | 2022-04-28 | 한미약품 주식회사 | 안정성 및 용출율이 개선된 타다라필 및 탐수로신 함유 캡슐 복합제제 |
| EP3473244A1 (de) | 2017-10-20 | 2019-04-24 | Veru Inc. | Orales tamsulosinhydrochlorid mit kontrollierter freisetzung |
| EP3473245A1 (de) | 2017-10-20 | 2019-04-24 | Veru Inc. | Orales tamsulosinhydrochlorid mit kontrollierter freisetzung |
| EP4422599A1 (de) | 2021-10-25 | 2024-09-04 | Farmalider, S.A. | Orale suspension von tadalafil |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56110665A (en) | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
| JPS61100526A (ja) * | 1984-10-22 | 1986-05-19 | Kyowa Hakko Kogyo Co Ltd | 持続性ドパミン経黒剤 |
| US4772475A (en) * | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
| IE60311B1 (en) | 1987-09-24 | 1994-06-29 | American Home Prod | Sustained release etodolac |
| JPH07316077A (ja) * | 1994-05-20 | 1995-12-05 | Sumitomo Pharmaceut Co Ltd | 腸溶性コーティング用組成物 |
| US6177430B1 (en) * | 1997-03-27 | 2001-01-23 | Pfizer Inc | Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia |
| AR023700A1 (es) * | 1998-11-12 | 2002-09-04 | Smithkline Beecham Plc | Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina |
| EP1064938A1 (de) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf |
| JP3154710B1 (ja) * | 1999-08-09 | 2001-04-09 | 山之内製薬株式会社 | 下部尿路症治療剤 |
| KR20020016944A (ko) * | 1999-08-09 | 2002-03-06 | 오노다 마사요시 | 하부 요로증 치료용 의약 조성물 |
| ATE376414T1 (de) * | 1999-09-02 | 2007-11-15 | Nostrum Pharmaceuticals Inc | Pellet formulierung mit gesteuerter freisetzung |
| US6368628B1 (en) | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
| US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| SI1443917T1 (sl) * | 2001-11-07 | 2006-06-30 | Synthon Bv | Tablete tamsulozina |
| US7018658B2 (en) * | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
-
2002
- 2002-11-14 US US10/293,940 patent/US7018658B2/en not_active Expired - Lifetime
- 2002-12-12 DE DE20219293U patent/DE20219293U1/de not_active Ceased
- 2002-12-12 PT PT02786241T patent/PT1562573E/pt unknown
- 2002-12-12 WO PCT/NL2002/000821 patent/WO2004043449A1/en active IP Right Grant
- 2002-12-12 AT AT02786241T patent/ATE323478T1/de active
- 2002-12-12 GB GB0229021A patent/GB2395125B/en not_active Expired - Lifetime
- 2002-12-12 DK DK02786241T patent/DK1562573T3/da active
- 2002-12-12 EP EP02786241A patent/EP1562573B1/de not_active Revoked
- 2002-12-12 HU HU0500832A patent/HUP0500832A3/hu unknown
- 2002-12-12 DE DE60210828T patent/DE60210828T2/de not_active Expired - Lifetime
- 2002-12-12 NL NL1022151A patent/NL1022151C2/nl not_active IP Right Cessation
- 2002-12-12 JP JP2004551288A patent/JP5405710B2/ja not_active Expired - Lifetime
- 2002-12-12 ES ES02786241T patent/ES2257589T3/es not_active Expired - Lifetime
- 2002-12-12 AU AU2002351451A patent/AU2002351451A1/en not_active Abandoned
- 2002-12-16 FI FI20020500U patent/FI5842U1/fi active
- 2002-12-17 CZ CZ200213764U patent/CZ13341U1/cs not_active IP Right Cessation
- 2002-12-18 PL PL357856A patent/PL206083B1/pl unknown
- 2002-12-27 SI SI200200319A patent/SI21394A2/sl unknown
- 2002-12-30 CH CH02222/02A patent/CH696419A5/de not_active IP Right Cessation
-
2003
- 2003-01-02 AT AT0000203U patent/AT6542U1/de not_active IP Right Cessation
- 2003-01-08 DK DK200300005U patent/DK200300005U3/da active
- 2003-01-08 CA CA002415840A patent/CA2415840C/en not_active Expired - Lifetime
- 2003-01-09 AU AU2003200059A patent/AU2003200059B2/en not_active Expired
- 2003-01-22 FR FR0300651A patent/FR2847166B1/fr not_active Expired - Lifetime
- 2003-03-24 BE BE2003/0184A patent/BE1015435A4/nl not_active IP Right Cessation
- 2003-11-13 AU AU2003288083A patent/AU2003288083A1/en not_active Abandoned
- 2003-11-13 WO PCT/EP2003/012829 patent/WO2004043448A1/en not_active Application Discontinuation
-
2005
- 2005-05-09 ZA ZA200503696A patent/ZA200503696B/en unknown
- 2005-06-13 NO NO20052860A patent/NO20052860L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052860L (no) | Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme | |
| RU2127587C1 (ru) | Устойчивые лекарственные формы с регулируемым выделением, имеющие акриловые полимерные покрытия, (варианты) и способ их получения | |
| ATE380022T1 (de) | Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen | |
| WO2004022031A3 (en) | Stable probiotic microsphere compositions and their methods of preparation | |
| CA2382098C (en) | Sustained-release, oral pharmaceutical forms of administration | |
| AU593259B2 (en) | Solid, stable dosage forms with an elastic film coating | |
| US4367217A (en) | Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof | |
| JP4819362B2 (ja) | 中性コアおよびメタクリレートコポリマーおよびメタクリレートモノマーからなる内部被膜および外部被膜からなる作用物質を含有する多層薬剤形 | |
| ATE376414T1 (de) | Pellet formulierung mit gesteuerter freisetzung | |
| WO2015193788A1 (en) | Formulation for oral administration containing mesalazine | |
| NO792335L (no) | Legemiddel-retardform med uopploeselige, poroese diffusjonsovertrekk | |
| JP2007507553A5 (de) | ||
| NO20062082L (no) | Pellets inneholdende venlafaksinhydroklorid | |
| WO2007072495A3 (en) | Coated tablets having prolonged gastric retention | |
| ATE243026T1 (de) | Bupropion-darreichungsform mit kontrollierter freisetzung | |
| RU2013125148A (ru) | Пероральная фармацевтическая таблетка с регулируемым высвобождением месалазина и способ ее получения | |
| NZ240853A (en) | Phased-release oral dosage form comprising an histamine receptor antagonist in a polymer matrix | |
| JP2018521030A5 (de) | ||
| CA2555295A1 (en) | Extended release coated mini-tablets of venlafaxine hydrochloride | |
| ATE344659T1 (de) | Tablettenzubereitung mit verlängerter freisetzung von venlafaxin | |
| JPS58109413A (ja) | 耐衝撃性腸溶錠 | |
| WO2007015270A3 (en) | Novel controlled release compositions of selective serotonin reuptake inhibitors | |
| JP2008260778A (ja) | フィルムコーティング錠剤 | |
| SU1478993A3 (ru) | Способ получени микрогранул | |
| WO2006072424A1 (en) | PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF β-LACTAM ANTIBIOTICS IN COMBINATION WITH β-LACTAMASE INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |